- Home
- SEGG vs CDT Comparison
SEGG vs CDT Comparison
Compare SEGG & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | CDT |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | 12 | 6 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 22.1M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SEGG | CDT |
|---|---|---|
| Price | $2.20 | $1.27 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 32.9K |
| Earning Date | 05-20-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.37 |
| 52 Week High | $7.61 | $11.00 |
Technical Indicators
Market Signals| Indicator | SEGG | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 72.05 | 35.08 |
| Support Level | $0.74 | $1.24 |
| Resistance Level | $4.90 | $1.66 |
| Average True Range (ATR) | 0.32 | 0.22 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 75.31 | 6.91 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is a sports, entertainment and gaming group operating digital assets such as Sports.com and Lottery.com. It is focused on immersive fan engagement, ethical gaming and AI-driven live experiences.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.